These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34675225)

  • 1. Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement.
    Rosen J; Stoffels G; Lohmann P; Bauer EK; Werner JM; Wollring M; Rapp M; Felsberg J; Kocher M; Fink GR; Langen KJ; Galldiks N
    Sci Rep; 2021 Oct; 11(1):20828. PubMed ID: 34675225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
    Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Treatment Response Assessment Using
    Ceccon G; Lohmann P; Werner JM; Tscherpel C; Dunkl V; Stoffels G; Rosen J; Rapp M; Sabel M; Herrlinger U; Schäfer N; Shah NJ; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2021 Jul; 62(7):918-925. PubMed ID: 33158907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
    Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
    J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic Heterogeneity by Compartmental Uptake Characteristics in Preoperative Glioma Using
    Lohmeier J; Radbruch H; Brenner W; Hamm B; Tietze A; Makowski MR
    J Nucl Med; 2023 Nov; 64(11):1683-1689. PubMed ID: 37652542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Static and dynamic
    Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of [
    Shymanskaya A; Worthoff WA; Stoffels G; Lindemeyer J; Neumaier B; Lohmann P; Galldiks N; Langen KJ; Shah NJ
    Mol Imaging Biol; 2020 Feb; 22(1):198-207. PubMed ID: 30989437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
    Verburg N; Koopman T; Yaqub MM; Hoekstra OS; Lammertsma AA; Barkhof F; Pouwels PJW; Reijneveld JC; Heimans JJ; Rozemuller AJM; Bruynzeel AME; Lagerwaard F; Vandertop WP; Boellaard R; Wesseling P; de Witt Hamer PC
    Neuro Oncol; 2020 Mar; 22(3):412-422. PubMed ID: 31550353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
    Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.
    Pyka T; Gempt J; Hiob D; Ringel F; Schlegel J; Bette S; Wester HJ; Meyer B; Förster S
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):133-141. PubMed ID: 26219871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
    Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
    Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential implementation of DSC-MR perfusion and dynamic [
    Steidl E; Langen KJ; Hmeidan SA; Polomac N; Filss CP; Galldiks N; Lohmann P; Keil F; Filipski K; Mottaghy FM; Shah NJ; Steinbach JP; Hattingen E; Maurer GD
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1956-1965. PubMed ID: 33241456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.